Blocking anti‐apoptosis as a strategy for cancer chemotherapy: NF‐κB as a target
- 6 May 2004
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 92 (4) , 646-650
- https://doi.org/10.1002/jcb.20080
Abstract
Critical processes underlying cancers must be better understood to develop strategies for treatment and prevention. A chemotherapeutic strategy is proposed that is based upon re‐establishment, with a drug, of nullified programmed cell death (apoptosis) in cancer cells, which to survive have mutated to block apoptosis. A chemotherapy that is specific against tumors implanted in mice demonstrated the feasibility of this principle. This therapy is specific because it affects a process unique to cancer cells. It also has the advantage of killing these cells, in contrast to reversibly blocking their proliferation. The anti‐apoptotic transcription factor NF‐κB provides a potential therapeutic target in estrogen receptor negative (ER−) breast cancers that over‐express the epidermal growth factor family of receptors (EGFR). Further investigations of the pathways utilize dominant negative protein inhibitory peptide, and small inhibitory RNAs (siRNAs) to block the production of relevant enzymes.Keywords
This publication has 33 references indexed in Scilit:
- IκB Kinase-Independent IκBα Degradation Pathway: Functional NF-κB Activity and Implications for Cancer TherapyMolecular and Cellular Biology, 2003
- Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibitionBiochemical Journal, 2003
- Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival PathwayJournal of Biological Chemistry, 2003
- Overcoming Antiapoptotic Responses to Promote Chemosensitivity in Metastatic Colorectal Cancer to the LiverAnnals of Surgical Oncology, 2003
- Cell Cycle Effects and Caspase-Dependent and Independent Death of HL-60 and Jurkat Cells Treated with the Inhibitor of NF-6B ParthenolideCell Cycle, 2003
- Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathwayOncogene, 2003
- NF-κB and breast cancerCurrent Problems in Cancer, 2002
- Inhibition of protein kinase B/AktPharmacology & Therapeutics, 2002
- Identification of Signal-induced IκB-α Kinases in Human Endothelial CellsJournal of Biological Chemistry, 1996
- Characterization of IκB KinasesJournal of Biological Chemistry, 1996